139 results
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
profitability2
Mr. Campbell will discuss the Amicus corporate objectives and key milestones in a presentation at the 42nd Annual J.P. Morgan Healthcare
8-K
3mdhu8 4up85ja5twcjl
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
EX-99.2
lsnpwprlfabtt4sct7u
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
S-3ASR
b4n2u06oz2ipyqcv9f
8 Nov 23
Automatic shelf registration
5:25pm
8-K
EX-10.1
09dj5h 7l614l5
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
5jz qpa7ld2p
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
EX-99.1
yw51s
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
8gc0e1 y9
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.1
zmr 8zxh146
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
ssya32v
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
qr9lpdnt
1 Aug 22
Departure of Directors or Certain Officers
5:10pm